PDRN CareAdenosine Receptors
Dr. Sarah Chen
PhD, Molecular Biology
Adenosine receptors are a family of four G-protein coupled receptors (GPCRs) β designated A1, A2A, A2B, and A3 β that mediate the physiological effects of extracellular adenosine across virtually all human tissues [1].
Definition
Adenosine receptors are a family of four G-protein coupled receptors (GPCRs) β designated A1, A2A, A2B, and A3 β that mediate the physiological effects of extracellular adenosine across virtually all human tissues [1]. These receptors regulate a wide range of biological processes including inflammation, vasodilation, neurotransmission, immune cell function, and tissue repair [1][5]. In the context of PDRN therapy, the adenosine A2A receptor is the primary molecular target responsible for the regenerative and anti-inflammatory outcomes observed in clinical applications [2].
A1 Receptor (ADORA1)
The A1 receptor is coupled to inhibitory G-proteins (Gi/o) and is highly expressed in the brain, heart, kidney, and adipose tissue [1][5]. Activation of A1 receptors decreases intracellular cAMP and reduces adenylyl cyclase activity. In the cardiovascular system, A1 signaling slows heart rate and reduces atrioventricular conduction. In skin, A1 receptors are expressed at lower levels on keratinocytes and dermal fibroblasts, where they may play a modulatory role in proliferation [3]. The A1 receptor has a high affinity for adenosine, responding to basal physiological concentrations in the nanomolar range [1].
A2A Receptor (ADORA2A)
The A2A receptor is the most pharmacologically significant adenosine receptor for regenerative medicine and the primary target of PDRN [2][4]. It is coupled to stimulatory G-proteins (Gs) and activates adenylyl cyclase, increasing intracellular cAMP upon ligand binding [1]. The A2A receptor is abundantly expressed on fibroblasts, endothelial cells, macrophages, neutrophils, T-cells, and dendritic cells [5]. When PDRN fragments bind the A2A receptor, three principal downstream effects occur: (1) fibroblast proliferation and enhanced collagen synthesis through CREB-mediated gene transcription; (2) suppression of pro-inflammatory cytokines including TNF-alpha, IL-6, and NF-kB, shifting the tissue microenvironment from inflammatory to reparative; and (3) upregulation of VEGF expression in endothelial cells, promoting angiogenesis and restoring microcirculation to damaged tissue [2][4]. The A2A receptor has intermediate affinity for adenosine, activated at concentrations that rise during tissue injury or metabolic stress [1].
A2B Receptor (ADORA2B)
The A2B receptor, like A2A, is coupled to Gs proteins and increases cAMP upon activation [1]. However, it has the lowest affinity for adenosine among the four subtypes, requiring micromolar concentrations for significant activation β levels typically reached only during hypoxia, ischemia, or severe inflammation [5]. A2B receptors are expressed on fibroblasts, mast cells, bronchial smooth muscle, and intestinal epithelial cells. In skin biology, A2B activation has been linked to mast cell degranulation modulation and fibrotic responses [3]. While A2B signaling can contribute to tissue repair under extreme stress conditions, it also promotes fibrosis when chronically stimulated, making it a less desirable therapeutic target compared to A2A [5].
A3 Receptor (ADORA3)
The A3 receptor is coupled to Gi/o proteins and signals through multiple pathways including phospholipase C activation and intracellular calcium mobilization [1]. It is expressed on mast cells, eosinophils, lymphocytes, and certain epithelial cells. A3 receptor activation plays complex roles in inflammation β it can be either pro-inflammatory or anti-inflammatory depending on the cellular context and activation intensity [5]. In dermatology, A3 receptor agonists have been investigated for psoriasis treatment due to their ability to modulate keratinocyte proliferation and immune cell activity [3]. The A3 receptor has relatively low affinity for adenosine and is the least conserved subtype across mammalian species [1].
Why PDRN Targets the A2A Receptor
PDRN's therapeutic profile is fundamentally determined by its preferential activation of the A2A receptor [2]. This selectivity arises from the molecular fragments generated during enzymatic degradation of PDRN's polynucleotide chains β the released deoxyribonucleosides structurally mimic adenosine and engage the A2A binding site with sufficient affinity to trigger sustained downstream signaling [2][4]. The beauty of PDRN's A2A agonism lies in its self-limiting pharmacology: as the polymer chains are gradually cleaved, A2A stimulation occurs locally and proportionally to the metabolic activity of the surrounding tissue, avoiding the systemic effects associated with small-molecule A2A agonists [2].
Clinical Relevance
Understanding the adenosine receptor family explains why PDRN produces such a specific set of clinical outcomes β enhanced collagen production, reduced inflammation, and improved vascularity β rather than the broad physiological effects associated with systemic adenosine signaling [2][4]. It also clarifies why PDRN-based treatments are safe: by acting locally on A2A receptors at the injection or application site, PDRN avoids engagement of cardiac A1 receptors, pulmonary A2B receptors, and other off-target pathways that would complicate systemic adenosine receptor agonism [2][3].
References
- [1]Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors. Pharmacol Rev. 2011;63(1):1-34. doi:10.1124/pr.110.003285
- [2]Squadrito F, Bitto A, Irrera N, et al.. Pharmacological Activity and Clinical Use of PDRN. Curr Pharm Des. 2017;23(27):3948-3957. doi:10.2174/1381612823666170516153716
- [3]Chen JF, Eltzschig HK, Bhatt S. Purinergic signaling in health and disease. Nat Rev Drug Discov. 2013;12(4):265-286. doi:10.1038/nrd3950
- [4]Bitto A, Polito F, Irrera N, et al.. Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A2A receptor. Arthritis Res Ther. 2011;13(1):R28. doi:10.1186/ar3254
- [5]Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev. 2018;98(3):1591-1625. doi:10.1152/physrev.00049.2017